Back to discover

Protein / target

Myosin regulatory light chain 2, ventricular/cardiac muscle isoform

Encoded byMYL2P10916Homo sapiensSwiss-Prot
UniProt: P10916Ensembl: ENSG00000111245HGNC: HGNC:7583NCBI Gene: 4633
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Structural constituent of muscle

Strongest disease association

Hypertrophic cardiomyopathy 10

Via encoding gene MYL2 · Genetic evidence · score 0.92

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Contractile protein that plays a role in heart development and function.

View complete UniProt function annotation

Contractile protein that plays a role in heart development and function (PubMed:23365102, PubMed:32453731). Following phosphorylation, plays a role in cross-bridge cycling kinetics and cardiac muscle contraction by increasing myosin lever arm stiffness and promoting myosin head diffusion; as a consequence of the increase in maximum contraction force and calcium sensitivity of contraction force. These events altogether slow down myosin kinetics and prolong duty cycle resulting in accumulated myosins being cooperatively recruited to actin binding sites to sustain thin filament activation as a means to fine-tune myofilament calcium sensitivity to force (By similarity). During cardiogenesis plays an early role in cardiac contractility by promoting cardiac myofibril assembly (By similarity)

Subcellular location

Cytoplasm, myofibril, sarcomere, A band
Domains and Gene Ontology detail (25)

Domains & features

EF-hand 1EF-hand 2EF-hand 3

Gene Ontology

  • CA band
  • Ccardiac myofibril
  • Ccytoplasm
  • Ccytoskeleton
  • Ccytosol
  • Cmyofibril
  • Cmyosin complex
  • Csarcomere
  • Factin monomer binding
  • Fcalcium ion binding
  • Fmyosin heavy chain binding
  • Fstructural constituent of muscle

166 aa · 19 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Muscle contractionUniProt · GO · Reactome
View supporting evidence

Muscle contraction

  • ·Contractile protein that plays a role in heart development and function (PubMed:23365102…
  • ·Cytoplasm, myofibril, sarcomere, A band
  • ·sarcomere
  • ·cardiac muscle contraction
View underlying pathways (1)
Striated Muscle Contraction

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

MYH7MYL3MYH6ACTC1ROCK2MYLK3MYLK2MYL4MYL1MYH9MYL2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Cardiomyopathy, Hypertrophic1 medicine
mavacamten
Broader indication categories (1)
Cardiovascular Diseases1 medicine
mavacamten

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

2 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

omecamtiv mecarbil
ApprovedActivator

Cardiac myosin activator

Acts on a complex — shared with MYH7, MYH6, MYH7B +3 more · 1 of 7 recorded protein targets

mavacamten
ApprovedInhibitor

Cardiac myosin inhibitor

Indicated for Cardiomyopathy, Hypertrophic, Cardiovascular Diseases

Acts on a complex — shared with MYH7, MYH6, MYH7B +3 more · 1 of 7 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MYL2

Gene-level evidence surfaced through the gene MYL2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Cardiomyopathy, Hypertrophic
0.97Well supported

Genetic evidence dominant · Open Targets 0.78

Hypertrophic cardiomyopathy 10
0.94Well supported

Genetic evidence dominant · Open Targets 0.79

Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy
0.87Well supported

Genetic evidence dominant · Open Targets 0.69

Cardiomyopathies
0.86Well supported

Genetic evidence dominant · Open Targets 0.52

Familial hypertrophic cardiomyopathy
0.76Well supported

Genetic evidence dominant · Open Targets 0.46

View evidence synthesis (5)
Cardiomyopathy, HypertrophicWell supported
0.97
agreement 0.88–1.00
Genetic46%Clinical37%Animal model15%Literature1%Genetic literaturedup

Open Targets aggregate 0.78 · 4 independent evidence families · 1 not counted as duplicate

Hypertrophic cardiomyopathy 10Well supported
0.94
agreement 0.81–1.00
Genetic85%Animal model15%Genetic literaturedup

Open Targets aggregate 0.79 · 2 independent evidence families · 1 not counted as duplicate

Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathyWell supported
0.87
agreement 0.75–1.00
Genetic83%Animal model17%Genetic literaturedup

Open Targets aggregate 0.69 · 2 independent evidence families · 1 not counted as duplicate

CardiomyopathiesWell supported
0.86
agreement 0.72–1.00
Genetic97%Literature3%

Open Targets aggregate 0.52 · 2 independent evidence families

Familial hypertrophic cardiomyopathyWell supported
0.76
agreement 0.62–0.90
Genetic98%Literature2%

Open Targets aggregate 0.46 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypertrophic cardiomyopathy 100.79
Cardiomyopathy, Hypertrophic0.78
Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy0.69
Cardiomyopathies0.52
Cardiovascular Diseases0.52
Congenital fiber-type disproportion myopathy0.50
Rare familial disorder with hypertrophic cardiomyopathy0.50
Familial hypertrophic cardiomyopathy0.46
Myocardial Infarction0.42

Drug development

3 compounds recorded · 2 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (3)
DANICAMTIVPhase 2 3
OMECAMTIV MECARBILApproval
MAVACAMTENApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Strong

Approved Drug and Structure with Ligand support this modality.

View underlying tractability evidence (2)
SM · Approved DrugSM · Structure with Ligand

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.PHASE4

NOT_YET_RECRUITING · via mavacamten · NCT07103655

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)PHASE3

RECRUITING · via omecamtiv mecarbil · NCT06736574

A Phase 4, Single-Arm, Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy in IndiaPHASE4

ACTIVE_NOT_RECRUITING · via mavacamten · NCT07004972

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure With Cardiac Magnetic Resonance Imaging (CMR)PHASE4

ACTIVE_NOT_RECRUITING · via mavacamten · NCT06112743

View all trials (26)
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic CardiomyopathyPHASE3

ACTIVE_NOT_RECRUITING · via mavacamten · NCT06253221

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in Hypertrophic Obstructive Cardiomyopathy: The PEACH TrialNA

RECRUITING · via mavacamten · NCT07120776

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy: A Randomized Controlled TrialNA

ACTIVE_NOT_RECRUITING · via mavacamten · NCT06947590

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNA

NOT_YET_RECRUITING · via mavacamten · NCT06856265

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic CardiomyopathyPHASE3

COMPLETED · via mavacamten · NCT05582395

A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyPHASE3

COMPLETED · via mavacamten · NCT05414175

A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyPHASE3

COMPLETED · via mavacamten · NCT05174416

Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HFPHASE3

WITHDRAWN · via omecamtiv mecarbil · NCT04464525

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction TherapyPHASE3

COMPLETED · via mavacamten · NCT04349072

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure With Reduced Ejection Fraction and Decreased Exercise TolerancePHASE3

COMPLETED · via omecamtiv mecarbil · NCT03759392

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)PHASE2/PHASE3

COMPLETED · via mavacamten · NCT03723655

A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyPHASE3

COMPLETED · via mavacamten · NCT03470545

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)PHASE3

COMPLETED · via omecamtiv mecarbil · NCT02929329

An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac BiomarkersPHASE2

COMPLETED · via mavacamten · NCT04766892

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)PHASE2

COMPLETED · via mavacamten · NCT03496168

A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection FractionPHASE2

COMPLETED · via mavacamten · NCT03442764

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionPHASE2

COMPLETED · via omecamtiv mecarbil · NCT02695420

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailurePHASE2

COMPLETED · via omecamtiv mecarbil · NCT01300013

An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart FailurePHASE2

WITHDRAWN · via omecamtiv mecarbil · NCT01077167

An Open-label, Randomized, Single-dose, 2-way Crossover Study to Establish Bioequivalence of 1 × 15-mg Mavacamten Capsule to 3 × 5-mg Mavacamten Capsules in Healthy ParticipantsPHASE1

COMPLETED · via mavacamten · NCT05719805

Bioequivalence Study of a Single Dose of 15-mg Mavacamten Capsule Versus a Single Dose of 3 x 5-mg Mavacamten Capsules in Healthy ParticipantsPHASE1

COMPLETED · via mavacamten · NCT05362045

An Open-label Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Pharmacokinetics of Mavacamten in Healthy ParticipantsPHASE1

COMPLETED · via mavacamten · NCT05320094

An Open-Label, Parallel-Group, Single-Center Phase 1 Clinical Study to Evaluate the Pharmacokinetics of a Single Oral Dose of Mavacamten in Healthy Adult Chinese SubjectsPHASE1

COMPLETED · via mavacamten · NCT05135871

Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT04175808

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese SubjectsPHASE1

COMPLETED · via omecamtiv mecarbil · NCT02601001

A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy VolunteersPHASE1

COMPLETED · via omecamtiv mecarbil · NCT01380223

ClinicalTrials.gov via the drug-target graph.

What's happening now

2

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2023-06-26

    Approval: Camzyos (EMA)

    ema · regulatory · ema · via mavacamten

  2. New publication2020-11-13
    Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

    The New England journal of medicine · 2021 · 443 citations · Europe PMC · via omecamtiv mecarbil

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.